La vendita allo scoperto per Simulations Plus dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Simulations Plus. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Simulations Plus (NASDAQ:SLP) Azioni, Report sulle vendite allo scoperto

Simulations Plus

Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Northeastern States Rank High

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ARVN

IOVA

Analizziamo le aziende con RSI basso, che potrebbero offrire interessanti opportunità di profitto nel mercato finanziario. Ecco i nomi.

3 titoli del settore sanitario destinati a decollare nel prossimo trimestre

Simulations Plus Inc

Smooth Love Potion - United States Dollar

SIMPLEX HLDGS INC by SIMPLEX HLDGS INC.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Arvinas Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>)</h3>
<ul>
<li>On March 11, Arvinas announced topline results from the phase 3 VERITAC-2 Trial of Vepdegestrant Monotherapy versus Fulvestrant in adults with advanced or retastatic breast cancer. The company's stock fell around 53% over the past month and has a <a href="https://www.benzinga.com/quote/ARVN">52-week low of $7.91</a>.</li>
<li>RSI Value: 25.9</li>
<li>ARVN Price Action: Shares of Arvinas fell 5.6% to close at $8.13 on <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Tuesday</a>. </li>
</ul>
<h3 class="wp-block-heading">Simulations Plus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>Simulations Plus will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3. The company's stock fell around 19% over the past month and <a href="https://www.benzinga.com/quote/SLP">has a 52-week low </a>of $24.00.</li>
<li>RSI Value: 29.7</li>
<li>SLP Price Action: Shares of Simulations Plus fell 3.2% to close at $24.72 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">SLP stock</a>. </li>
</ul>
<h3 class="wp-block-heading">Iovance Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>)</h3>
<ul>
<li>On March 21, Iovance Biotherapeutics reported inducement grants under NASDAQ listing rule 5635(c)(4). The company's stock fell around 35% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/IOVA">low of $3.42.</a></li>
<li>RSI Value: 26.7</li>
<li>IOVA Price Action: Shares of Iovance Biotherapeutics fell 4.1% to close at $3.48 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">IOVA shares</a>. </li>
</ul>
Learn more about BZ Edge Rankings—<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">click to see scores for other stocks in the sector and see how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44471817/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-3">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Top 3 Health Care Stocks That Are Set To Fly This Month

Keybanc analyst Brett Fishbin maintains Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight and raises the price target from $35 to $37.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Simulations Plus, Raises Price Target to $37

Industry partners to provide funding and data to support ACAT&#x2122; model improvements
Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform.
The collaboration focuses on enhancing the predictive capabilities of the GastroPlus advanced compartmental absorption and transit (ACAT&#x2122;) model to support the development of immediate release (IR) oral drug products. Using data gathered from public sources and members of the ETC, physiologically based pharmacokinetics (PBPK) and biopharmaceutics modeling (PBBM) experts and software engineers at Simulations Plus will look to complete key objectives as defined by the partnership. These advancements, including implementation of novel product-particle size distribution (P-PSD) methodologies and enhanced food effect modeling features, will provide researchers with powerful tools to improve drug product development, reduce reliance on animal studies, and streamline regulatory submissions.

Biotech

General

Simulations Plus And Enabling Technologies Consortium Announce Strategic Collaboration To Advance GastroPlus Enhancements

WIIM

Simulations Plus shares are trading lower after Keybanc cut its price target on the stock from $40 to $35.

Keybanc analyst Scott Schoenhaus maintains Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight and lowers the price target from $40 to $35.

Keybanc Maintains Overweight on Simulations Plus, Lowers Price Target to $35

The Q1 earnings report for Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) was released on Tuesday, January 7, 2025 at 04:06 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Simulations Plus missed estimated earnings by 0.0%, reporting an EPS of $0.17 versus an estimate of $0.17.
Revenue was up $4.42 million from the same period last year.
<h3>Earnings History Overview</h3>
Last quarter the company beat on EPS by $0.03 which was followed by a 9.0% drop in the share price the next day.
Here's a look at Simulations Plus's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>0.15</td>
<td>0.19</td>
<td>0.1</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.06</td>
<td>0.19</td>
<td>0.20</td>
<td>0.1</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>19.74M</td>
<td>17.96M</td>
<td>17.28M</td>
<td>13.93M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>18.70M</td>
<td>18.54M</td>
<td>18.30M</td>
<td>14.50M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Simulations Plus <a href="https://www.benzinga.com/quote/SLP/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Simulations Plus Q1 Earnings Assessment

Guidance

Simulations Plus Sees FY25 Revenue $90M-$93M Vs $90.692M Estimate; Sees Adj. EPS $1.07-$1.20 Vs $0.90 Estimate

Simulations Plus shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.11 by 54.55 percent. The company reported quarterly sales of $18.90 million which beat the analyst consensus estimate of $18.81 million by 0.50 percent. This is a 30.34 percent increase over sales of $14.50 million the same period last year.

Earnings Beats

Simulations Plus Q1 2025 Adj EPS $0.17 Beats $0.11 Estimate, Sales $18.90M Beat $18.81M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Lindsay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNN#NYSE">LNN</a>) is estimated to report quarterly earnings at $1.39 per share on revenue of $169.78 million. 
• Apogee Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $332.19 million. 
• RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) is likely to report quarterly earnings at $1.34 per share on revenue of $1.79 billion. 
<h3>Companies Reporting After The Bell</h3>
• Richardson Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELL#NASDAQ">RELL</a>) is projected to report quarterly loss at $0.02 per share on revenue of $51.31 million. 
• AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) is expected to report quarterly earnings at $1.27 per share on revenue of $396.64 million. 
• Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) is projected to report quarterly earnings at $0.17 per share on revenue of $18.80 million. 
• Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $61.72 million. 
• Cal-Maine Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) is estimated to report quarterly earnings at $3.68 per share on revenue of $751.50 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $654.09 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APOG

CALM

KRUS

RELL

Earnings Scheduled For January 7, 2025

Rumors

Watching Simulations Plus; Traders Circulate Stock Picked By Zacks Homerun Newsletter

Stephens &amp; Co. analyst Jeff Garro initiates coverage on Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Overweight rating and announces Price Target of $39.

Initiation

Stephens & Co. Initiates Coverage On Simulations Plus with Overweight Rating, Announces Price Target of $39

Simulations Plus And University Of Connecticut Receive FDA Grant To Expand Mechanistic Modeling Approaches For Long-Acting Injectables Using PBPK Models To Improve Bioequivalence Predictions

William Blair analyst Max Smock reiterates Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Outperform.

Reiteration

William Blair Reiterates Outperform on Simulations Plus

Collaboration goal to develop alternative methods to assess clinical performance of product variants under different conditions

Simulations Plus And Partners Wins FDA Grant To Validate In Vitro-In Vivo Extrapolation Methods For Complex Formulations

BTIG analyst David Larsen maintains Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) with a Buy and lowers the price target from $60 to $50.

BTIG Maintains Buy on Simulations Plus, Lowers Price Target to $50

Simulations Plus shares are trading lower after the company reported worse-than-expected Q4 revenue results.

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 66.67 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $18.70 million which missed the analyst consensus estimate of $19.74 million by 5.27 percent. This is a 19.87 percent increase over sales of $15.60 million the same period last year.

Earnings Misses

Simulations Plus Q4 Adj $0.06 Beats $0.03 Estimate, Sales $18.70M Miss $19.74M Estimate

Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) is looking for FY2025 Adj EPS of $1.07-1.20. sees sales of $90.000 million-93.000 million vs $91.75 million estimate.

Comments

Simulations Plus

Vendite allo scoperto

Simulations Plus (NASDAQ:SLP) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO